Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients

Patrice Chevallier; Maxime Jullien; Pierre Peterlin; Alice Garnier; Amandine Le Bourgeois; Marianne Coste-Burel; Marie C Béné; Thierry Guillaume

doi:10.1002/hon.3006

Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients

Hematol Oncol. 2022 Dec;40(5):1097-1099. doi: 10.1002/hon.3006. Epub 2022 Apr 29.

Authors

Patrice Chevallier^{1

2}, Maxime Jullien¹, Pierre Peterlin¹, Alice Garnier¹, Amandine Le Bourgeois¹, Marianne Coste-Burel³, Marie C Béné^{2

4}, Thierry Guillaume^{1

2}

Affiliations

¹ Hematology Department, Nantes University Hospital, Nantes, France.
² INSERM UMR1232, CRCINA IRS-UN, University of Nantes, Nantes, France.
³ Virology0020Department, Nantes University Hospital, Nantes, France.
⁴ Hematology Biology, Nantes University Hospital, Nantes, France.

Abstract

This study reports the effectiveness of three injections of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in 141 Allo-HSCT recipients with a median follow-up of 6 months post-third shot. We demonstrate a long-term high protection of Allo-HSCT recipients since only 2 infections and one death related to COVID-19 occurred.

Publication types

Letter

MeSH terms

BNT162 Vaccine*
COVID-19* / prevention & control
Hematopoietic Stem Cells
Humans
mRNA Vaccines

Substances

BNT162 Vaccine